SCHEMBL565491

SCHEMBL565491

CC(C)CN(Cc1cc(Br)c2c(c1)OCCCO2)C(=O)C1CN(Cc2ccccc2)C1

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 5/20 0.54
KDM4E B2RXH2 4/20 0.41
S1PR1 P21453 6/20 0.38
S1PR5 Q9H228 5/20 0.38
S1PR3 Q99500 2/20 0.38
POLB P06746 1/20 0.37
CHRM5 P08912 1/20 0.37
ACHE P22303 1/20 0.36
S1PR4 O95977 1/20 0.36
HTT P42858 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
PKM P14618 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL565068 0.93 PROKR2 (0.63) PROKR2KDM4EPOLBCHRM5ACHE
SCHEMBL564878 0.91 PROKR2 (0.63) PROKR2KDM4ES1PR1S1PR5S1PR3
SCHEMBL565162 0.88 PROKR2 (0.65) PROKR2KDM4EPOLBCHRM5ACHE
SCHEMBL565426 0.85 PROKR2 (0.73) PROKR2KDM4EPOLBCHRM5ACHE
SCHEMBL565136 0.85 PROKR2 (0.73) PROKR2KDM4EPOLBCHRM5ACHE
SCHEMBL565330 0.84 PROKR2 (0.73) PROKR2KDM4EPOLBCHRM5HTT
SCHEMBL565568 0.84 PROKR2 (0.73) PROKR2KDM4EPOLBCHRM5HTT
SCHEMBL565249 0.83 PROKR2 (0.63) PROKR2KDM4EPOLBCHRM5ACHE
SCHEMBL565334 0.83 PROKR2 (0.63) PROKR2KDM4EPOLBHTTMEN1
SCHEMBL564131 0.82 PROKR2 (0.69) PROKR2KDM4EPOLBCHRM5HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885KDM4E 4874/4885S1PR1 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.